Evidence map›Paper›PMID 30670599›Full record

ArticleThe oncologist2019

Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.

Pieter A Boonstra, Arja Ter Elst, Marco Tibbesma, Jourik A Gietema, Ed Schuuring, Anna K L Reyners

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Precision Oncology in Gastrointestinal Stromal Tumors.Current oncology (Toronto, Ont.) · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pieter A BoonstraDepartment of Medical Oncology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0002-1416-5143
Arja Ter ElstDepartment of Pathology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Marco TibbesmaDepartment of Pathology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jourik A GietemaDepartment of Medical Oncology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Ed SchuuringDepartment of Pathology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Anna K L ReynersDepartment of Medical Oncology, Medical Center Groningen, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands a.k.l.reyners@umcg.nl.
University Medical Center Groningen · NLUniversity of Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with a suspected malignancy, standard-of care management currently includes histopathologic examination and analysis of tumor-specific molecular abnormalities. Herein, we present a 77-year-old patient with an abdominal mass suspected to be a gastrointestinal stromal tumor (GIST) but without the possibility to collect a tumor biopsy. Cell-free DNA extracted from a blood sample was analyzed for the presence of mutations in GIST-specific genes using next generation sequencing. Furthermore, liquid biopsies were used to monitor the levels of mutant DNA copies during treatment with a tumor-specific mutation droplet digital PCR assay that correlated with the clinical and radiological response. Blood-based testing is a good alternative for biopsy-based testing. However, it should only be applied when biopsies are not available or possible to obtain because overall, in only 50%-85% of the cell-free plasma samples is the known tumor mutation detected.

Indexed as

MutationAgedAntineoplastic AgentsBiomarkers, TumorCirculating Tumor DNAFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHigh-Throughput Nucleotide SequencingHumansImatinib MesylateLiquid BiopsyPolymerase Chain ReactionPrognosisReceptor, Platelet-Derived Growth Factor alphaAntineoplastic AgentsBiomarkers, TumorCirculating Tumor DNAImatinib MesylateReceptor, Platelet-Derived Growth Factor alpha

Identifiers

PMID30670599
PMCPMC6656511
OpenAlexW2912915793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.